4,5-二氨基-6-氯嘧啶 | 4316-98-7

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4,5-二氨基-6-氯嘧啶
• 中文别名: 6-氯-4,5-嘧啶二胺；6-氯-4,5-二氨基嘧啶
• 英文名称: 6-chloro-4,5-diaminopyrimidine
• 英文别名: 6-chloropyrimidine-4,5-diamine；4,5-Diamino-6-chlor-pyrimidin；4,5-diamino-6-chloropyrimidine
• CAS: 4316-98-7
• 化学式: C₄H₅ClN₄
• mdl: MFCD00023270
• 分子量: 144.564
• InChiKey: VNSFICAUILKARD-UHFFFAOYSA-N

物化性质

• 熔点：
  252 °C (decomp)
• 沸点：
  336.7±37.0 °C(Predicted)
• 密度：
  1.565
• 闪点：
  157℃
• 溶解度：
  DMSO（少量）、甲醇（少量）
• 最大波长(λmax)：
  305nm(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存放于惰性气体中，避免接触空气。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Chloropyrimidine-4,5-diamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloropyrimidine-4,5-diamine
CAS number: 4316-98-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H5ClN4
Molecular weight: 144.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4,5-二氨基-6-氯嘧啶 在 氢碘酸 作用下， 以 水 为溶剂， 反应 24.5h， 以98%的产率得到6-iodopyrimidine-4,5-diamine
  参考文献：
  名称：

  [EN] CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY
  [FR] PYRIDINES CONDENSEES ET PYRIMIDINES A ACTIVITE TIE2 (TEK)

  摘要：

  化合物的公式（I），其中A与其连接的碳原子一起形成一个融合的5-成员杂环芳烃环，其中所述的杂环芳烃环包含1个或2个从O、N和S中选择的杂原子，并且包含G的5-成员环与在公式（I）中标记为桥头碳#的A形成的环在间位连接；G从O、S和NR5中选择；Z从N和CR6中选择；Q1从可选择的取代芳基和杂环芳基中选择，取代基R1到R6如文本中所定义，用于在温血动物（如人）中产生抗血管生成作用。

  公开号：

  WO2004013141A1
• 作为产物：
  描述：

  4,5-二氨基-6-羟基嘧啶 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 反应 4.0h， 以15%的产率得到4,5-二氨基-6-氯嘧啶
  参考文献：
  名称：

  [EN] CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY
  [FR] PYRIDINES CONDENSEES ET PYRIMIDINES A ACTIVITE TIE2 (TEK)

  摘要：

  化合物的公式（I），其中A与其连接的碳原子一起形成一个融合的5-成员杂环芳烃环，其中所述的杂环芳烃环包含1个或2个从O、N和S中选择的杂原子，并且包含G的5-成员环与在公式（I）中标记为桥头碳#的A形成的环在间位连接；G从O、S和NR5中选择；Z从N和CR6中选择；Q1从可选择的取代芳基和杂环芳基中选择，取代基R1到R6如文本中所定义，用于在温血动物（如人）中产生抗血管生成作用。

  公开号：

  WO2004013141A1

文献信息

• [EN] TANK-BINDING KINASE INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE KINASES SE LIANT À TANK
  申请人：GILEAD SCIENCES INC

  公开号：WO2015187684A1

  公开（公告）日：2015-12-10

  Compounds having the following formula (I) and methods of their use and preparation are disclosed:

  揭示了具有以下化学式（I）的化合物及其使用和制备方法。
• [EN] METHOD FOR SYNTHESIZING DIVERSELY SUBSTITUTED PURINES<br/>[FR] PROCÉDÉ DE SYNTHÈSE DE PURINES À SUBSTITUTIONS DIVERSES
  申请人：UNIV GRENOBLE ALPES

  公开号：WO2018203099A1

  公开（公告）日：2018-11-08

  The present invention relates to a method for synthesizing diversely substituted purines starting from a pyrimidine. Formula (I). The method comprises the formation of an amidine group on the pyrimidine by implementing a Vilsmeier type reagent, the functionalization of the pyrimidine with an amine and the cyclization to form the purine nucleus. Optional steps can also be performed in order to further functionalize the molecule. The invention also relates to new purines and new intermediate product.

  本发明涉及一种从嘧啶开始合成多样取代嘌呤的方法。公式（I）。该方法包括通过实施Vilsmeier型试剂在嘧啶上形成酰胺基团，用胺对嘧啶进行官能化，并进行环化以形成嘌呤核。还可以执行可选步骤以进一步官能化分子。该发明还涉及新的嘌呤和新的中间产物。
• Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase
  作者：Stephanie M. Stanford、Michael A. Diaz、Robert J. Ardecky、Jiwen Zou、Tarmo Roosild、Zachary J. Holmes、Tiffany P. Nguyen、Michael P. Hedrick、Socorro Rodiles、April Guan、Stefan Grotegut、Eugenio Santelli、Thomas D. Y. Chung、Michael R. Jackson、Nunzio Bottini、Anthony B. Pinkerton

  DOI：10.1021/acs.jmedchem.0c02126

  日期：2021.5.13

  obesity is to inhibit the protein tyrosine phosphatases that negatively regulate insulin receptor signaling. The low-molecular-weight protein tyrosine phosphatase (LMPTP) acts as a critical promoter of insulin resistance in obesity by inhibiting phosphorylation of the liver insulin receptor activation motif. Here, we report development of a novel purine-based chemical series of LMPTP inhibitors. These compounds

  肥胖相关的胰岛素抵抗在 2 型糖尿病的发病机制中起核心作用。降低肥胖症患者胰岛素抵抗的一种有希望的方法是抑制对胰岛素受体信号传导产生负调节作用的蛋白酪氨酸磷酸酶。低分子量蛋白酪氨酸磷酸酶 (LMPTP) 通过抑制肝脏胰岛素受体激活基序的磷酸化，成为肥胖患者胰岛素抵抗的关键促进剂。在这里，我们报告了一种新型的基于嘌呤的化学系列 LMPTP 抑制剂的开发。这些化合物以非竞争性机制抑制 LMPTP，并且对 LMPTP 的选择性高于其他蛋白酪氨酸磷酸酶。我们还报告了一种高度口服生物可利用的嘌呤类似物的产生，该类似物可逆转小鼠肥胖引起的糖尿病。
• 伊曲茶碱类衍生物及其制备方法和应用
  申请人：山东新华制药股份有限公司

  公开号：CN112209930B

  公开（公告）日：2023-05-16

  本发明提供了伊曲茶碱衍生物及其制备方法和应用，包含所述化合物的药理活性，为了满足多种剂型的要求，同时为了寻找药理活性相当或更优的候选化合物，以伊曲茶碱为先导化合物，在保持伊曲茶碱药效基团杂环中心不变的前提下，对其进行结构修饰，并对所得到的化合物进行药理活性筛选，以期获得药理活性更优、毒副作用更小的候选药物；本发明还涉及提供一种新型选择性腺苷A2A受体拮抗药的新化合物的生物活性研究方法。
• Novel 2-phenyl-imidazoles and pharmaceutical compositions containing same
  申请人：Dr. Karl Thomae GmbH

  公开号：US04722929A1

  公开（公告）日：1988-02-02

  The invention relates to novel 2-phenyl-imidazoles of the formula ##STR1## and the tautomers and acid addition salts thereof, particularly the pharmacologically acceptable acid addition salts, which exhibit valuable pharmacological properties, particularly an effect on the contractility of the heart muscle. The compounds of Formula I may be prepared by methods conventionally used for similar compounds.

  本发明涉及新型2-苯基咪唑及其互变异构体和酸加成盐，特别是具有药用价值的酸加成盐，尤其是对心肌收缩力具有显著效果的药物。公式I的化合物可以通过通常用于类似化合物的方法来制备。

表征谱图